McGill University has contributed significantly to venous thrombosis research through the COBRRA trial, demonstrating the safety of apixaban over rivaroxaban.
The Impact of Heart Competitions on Cardiovascular Health
Introduction The emergence of heart competitions is reshaping how communities engage with cardiovascular health and innovations in medical technology. As cardiac diseases remain one of the leading causes of mortality worldwide, initiatives that challenge individuals and organisations to improve heart health are gaining traction. Heart competitions not only focus on raising awareness but also encourage […]